Skip to content
ContentLora

    Tip: press / anywhere to search.

    Analysis

    The US mRNA vaccine policy debate, 2025-2026

    Since 2025 US health agencies have narrowed COVID-19 vaccine labels, ended BARDA mRNA investments and reconstituted the national vaccine advisory committee.[1][2][3] FDA and HHS leaders say the changes reflect the evidence on benefit for healthy people; critics, including medical societies that obtained a court stay in March 2026, say they harm science and preparedness. The stay is under appeal.[4][5][6][7][8] States have moved in different directions: some lawmakers proposed limits on mRNA vaccines, while other states changed laws to rely less on ACIP.[9][10]

    Editor reviewedStrict sourcingUpdated mRNA and next-gen vaccinesHealth and medicineTech policy
    Show:

    US federal policy on mRNA vaccines changed in several ways in 2025-2026, and one of those changes is now before a federal appeals court.[1][2][7][8] This page sets out what happened and the main competing readings, each in its proponents’ own terms. It gives no view on whether any individual should be vaccinated.

    What changed

    In May 2025 HHS cancelled federal funding for Moderna’s pandemic influenza vaccine work.[11] In June 2025 HHS Secretary Robert F. Kennedy Jr. removed the members of the Advisory Committee on Immunization Practices (ACIP). By early 2026, 13 of its 15 members had been appointed between June 2025 and January 2026.[3]

    In August 2025 HHS announced that BARDA was ending 22 mRNA vaccine investments worth about $500 million.[2] Some final-stage contracts continued.[12] The same month, the FDA limited Comirnaty’s label to people 65 and older and younger people with high-risk conditions.[1] It also required a placebo-controlled trial in healthy adults aged 50-64.[13] In September 2025 the reconstituted ACIP moved COVID-19 vaccination to individual-based decision-making for everyone 6 months and older.[14] In December 2025 CEPI agreed to fund a phase 3 trial of Moderna’s H5 pandemic flu vaccine candidate.[15]

    On 16 March 2026 a federal court stayed the ACIP appointments and the votes taken since June 2025.[7] The government appealed, and as of late September 2026 the case was pending in the First Circuit.[8] In August 2026 the FDA approved Moderna’s mRNA flu vaccine. In February it had first refused to file the application over its comparator, then accepted an amended application.[16][17]

    For the 2026-2027 season the FDA advised manufacturers to target the JN.1-lineage XFG variant.[18] On 27 August 2026 it approved updated Comirnaty, Spikevax and mNEXSPIKE, along with Novavax’s protein-based vaccine.[19] Eligibility stayed as set in 2025: everyone 65 and older and younger people with at least one high-risk condition.[20]

    The case for a higher evidence bar

    In an August 2025 memo the director of the FDA’s biologics centre concluded that there was substantial certainty of net benefit from the mRNA vaccine for people with risk factors, but not for healthy people.[4] The memo argued that antibody levels are a surrogate endpoint.[21] It said randomized trials measuring clinical outcomes would be required before approval for healthy people.[13] It also noted that most peer European countries no longer advise COVID-19 vaccination for healthy people.[22] HHS Secretary Kennedy said BARDA was ending the investments because “the data show these vaccines fail to protect effectively against upper respiratory infections,” and that funding would shift to other platforms.[5]

    The case that the changes harm science and preparedness

    A former BARDA director called the BARDA cancellations a “huge blow to our national security.” The Alliance for mRNA Medicines called them unscientific.[6] The American Academy of Pediatrics and other medical groups sued over the ACIP appointments. The court assessed the new members’ credentials, concluded that many lacked the requisite vaccine expertise, and described the appointments as “a rushed, informal process.” It stayed the appointments and the committee’s votes.[23][7] When the mRNA flu vaccine was approved, IDSA said the platform “allows for streamlined development and rapid responses to emerging mutations in viruses.”[24]

    State legislation

    State legislatures have also acted on mRNA vaccines and vaccine advice, in opposite directions. In 2025 Republican lawmakers in at least seven states introduced bills to ban or limit mRNA vaccines. Some would have imposed criminal penalties, fines or licence revocation on clinicians who gave the shots.[9] Other proposals targeted mandates or labelling, for example banning COVID-19 or mRNA vaccine mandates or requiring mRNA technology to be listed among product ingredients.[25] Supporters of bans argued that long-term safety data were lacking. Public health experts responded that the vaccines had been extensively studied and that a ban would weaken pandemic preparedness.[26] Montana’s 2025 bill to ban mRNA vaccines for humans did not pass.[27]

    In February 2026 the South Dakota House rejected a bill that would have barred employers and others from requiring “genetic-based vaccinations”, a term defined to include mRNA vaccines.[28] All six COVID-19-related bills in that state’s 2026 session failed, including one to label blood from donors who had received a COVID-19 or mRNA vaccine.[29]

    Other states moved the other way. According to the Association of State and Territorial Health Officials, eight states, including Colorado, Maryland and Washington, enacted laws in 2026 that change ACIP’s role in state vaccine policy. Several of these laws require insurers to cover vaccines recommended by bodies other than ACIP.[10] Maryland’s Vax Act, for example, requires the state health secretary to issue immunization recommendations based on evidence-based scientific and clinical guidance.[30]

    The state bills follow the same divide as the federal debate. Supporters of mRNA bans frame them around safety concerns, and opponents frame the bans as a risk to preparedness.[26] Washington titled its 2026 law as preserving access to preventive services, which frames the ACIP changes as protecting access while federal advice is contested.[31][8] Either way, where a person lives can increasingly affect which vaccine advice and coverage rules apply to them.

    The process and authority question

    In its First Circuit brief the government argues that ACIP appointments are not reviewable final agency action and that the plaintiffs lack standing. It also argues that the district court wrongly assessed appointees’ credentials one by one.[32] As of mid-September 2026 the reconstituted committee had not met since the ruling, according to press reports.[33]

    The disputes are connected but distinct. The FDA’s argument is about which endpoints are enough for approval in low-risk groups. The BARDA decision is about what federal money should fund. The ACIP case is about who gets to issue federal advice and how. The 2026 flu vaccine approval can be read two ways. Supporters of the changes can cite it as evidence that the FDA is applying a stricter standard rather than blocking a platform. Critics can cite the initial refusal to file and the new trial requirements as added uncertainty for developers. Both readings fit the same record.[16][17][13]

    The First Circuit ruling is probably the near-term event most likely to change federal recommendations. Either outcome could be appealed further, so uncertainty may last into 2027. Requirements for randomized outcome trials in healthy adults are likely to raise development costs for future updated COVID-19 vaccines. The results of the 50-64 placebo-controlled trial, which had not been reported in the sources reviewed, could either support broader use or reinforce the narrower labels.[13][8]

    This page describes policy and evidence. It is not medical advice.

    Competing views

    The evidence bar should be higher

    FDA leaders say net benefit is shown for higher-risk people but not for healthy people, and that antibody levels are only a surrogate, so they require outcome trials. HHS says the vaccines fail to protect effectively against upper respiratory infections.[4][21][13][5]

    The changes harm science and preparedness

    A former BARDA director and industry groups say the BARDA cuts harm national security and are unscientific. Medical societies obtained a court stay of the ACIP appointments. IDSA says mRNA allows rapid responses to viral mutations.[6][7][24]

    The core dispute is legal authority

    The district court found the ACIP appointments rushed and stayed them and the committee's votes. The government argues appointments are not reviewable and the court wrongly judged members' credentials. The appeal will decide who sets federal advice.[23][7][32][8]

    Questions readers ask

    Did the FDA ban mRNA COVID-19 vaccines?

    No. In August 2025 it approved updated Comirnaty for people 65 and older and people aged 5-64 with at least one high-risk condition, and required a placebo-controlled trial in healthy adults aged 50-64.[1][13]

    Why did HHS cancel BARDA's mRNA projects?

    HHS Secretary Robert F. Kennedy Jr. said the data show these vaccines "fail to protect effectively against upper respiratory infections," and that funding would move to other platforms. Some final-stage contracts continued.[5][12]

    What did the court rule about ACIP?

    On 16 March 2026 a federal court in Massachusetts stayed the 13 ACIP appointments and all votes of the reconstituted committee since June 2025. The government has appealed.[7][8]

    Are updated COVID-19 vaccines available for 2026-2027?

    On 27 August 2026 the FDA approved XFG-targeted 2026-2027 formulas of Comirnaty, Spikevax and mNEXSPIKE, and of Novavax's protein vaccine. Eligibility stayed limited to people 65 and older and younger people with high-risk conditions.[19][20]

    Have states passed laws against mRNA vaccines?

    Lawmakers in at least seven states introduced bills to ban or limit mRNA vaccines in 2025. Montana's ban bill did not pass, and in 2026 the South Dakota House rejected a bill barring requirements for mRNA and other "genetic-based" vaccines. Other states enacted laws reducing their reliance on ACIP.[9][27][28][10]

    Has the FDA approved any new mRNA vaccine since 2025?

    Yes. In August 2026 it approved Moderna's mRNA flu vaccine for adults 50 and older. In February it had first refused to file the application over the choice of comparator, then accepted an amended application.[16][17]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      In August 2025 the FDA limited the approved use of Pfizer-BioNTech's Comirnaty to people 65 and older and younger people with at least one condition that puts them at high risk of severe COVID-19. confirmedas of 2025-08-25

    2. [2]

      In August 2025 HHS announced that BARDA was terminating 22 mRNA vaccine development investments worth about $500 million. confirmedas of 2025-08-08

    3. [3]

      After Secretary Kennedy removed the existing ACIP members in June 2025, 13 of the 15 members serving by early 2026 had been appointed between June 2025 and January 2026. confirmedas of 2026-03-17

    4. [4]

      The FDA biologics center director's August 2025 memo concluded there was not substantial certainty of net benefit from vaccinating healthy people with the mRNA vaccine, but that there was for people with risk factors. confirmedas of 2025-08-25

    5. [5]

      HHS Secretary Robert F. Kennedy Jr. said the BARDA mRNA investments were ended because, in his view, the data show these vaccines fail to protect effectively against upper respiratory infections, and that funding would shift to other platforms such as whole-virus vaccines. confirmedas of 2025-08-08

    6. [6]

      Scientists and industry groups criticised the BARDA cancellations; a former BARDA director called it a blow to national security and the Alliance for mRNA Medicines called it unscientific. confirmedas of 2025-08-08

    7. [7]

      On 16 March 2026 a federal district court in Massachusetts, in American Academy of Pediatrics v. Kennedy, stayed the 13 ACIP appointments and all votes of the reconstituted committee since June 2025. confirmedas of 2026-03-17

    8. [8]

      The federal government appealed the March 2026 ruling to the First Circuit (No. 26-1503), and district court proceedings were paused pending the appeal. confirmedas of 2026-09-30

    9. [9]

      In 2025 Republican lawmakers in at least seven states introduced bills to ban or limit mRNA vaccines; some would have imposed criminal penalties, fines or licence revocation on clinicians who gave the shots. confirmedas of 2025-04-14

    10. [10]

      According to the Association of State and Territorial Health Officials, in 2026 Colorado, Connecticut, Maine, Maryland, New Mexico, Oregon, Vermont and Washington enacted laws modifying ACIP's role in state vaccine policy, several of them requiring insurers to cover vaccines recommended by bodies other than ACIP. reportedas of 2026-05-25

    11. [11]

      In May 2025 the US Department of Health and Human Services cancelled federal funding for Moderna's pandemic influenza vaccine development, including its H5 bird-flu candidate. confirmedas of 2025-12-18

    12. [12]

      HHS said some final-stage mRNA contracts would continue to preserve prior taxpayer investment. confirmedas of 2025-08-08

    13. [13]

      Under the FDA framework, approval for healthy people requires randomized trials measuring clinical outcomes; Pfizer-BioNTech agreed to a saline placebo-controlled trial in healthy adults aged 50-64. confirmedas of 2025-08-25

    14. [14]

      On 19 September 2025 ACIP voted to recommend COVID-19 vaccination based on individual-based (shared clinical) decision-making for people 6 months and older, and rejected a proposal to require prescriptions. confirmedas of 2025-09-19

    15. [15]

      In December 2025 CEPI agreed to provide up to $54.3 million for a phase 3 trial of Moderna's H5 pandemic influenza vaccine candidate mRNA-1018, and Moderna committed 20% of its H5 vaccine capacity to low- and middle-income countries at affordable prices. confirmedas of 2025-12-18

    16. [16]

      In August 2026 the FDA approved Moderna's mFLUSIVA (mRNA-1010) for adults 50 and older, the first mRNA-based influenza vaccine and Moderna's fourth FDA-approved product after Spikevax, mRESVIA and mNEXSPIKE. confirmedas of 2026-08-06

    17. [17]

      In February 2026 the FDA first refused to file Moderna's flu vaccine application, citing the choice of comparator vaccine for older adults rather than safety or efficacy concerns, then accepted an amended application about a week later. confirmedas of 2026-02-18

    18. [18]

      After its vaccine advisory committee met on 28 May 2026, the FDA advised manufacturers that 2026-2027 COVID-19 vaccines for the US should be monovalent vaccines targeting the JN.1-lineage XFG variant. confirmedas of 2026-05-29

    19. [19]

      On 27 August 2026 the FDA approved 2026-2027 formula versions of the mRNA vaccines Comirnaty, Spikevax and mNEXSPIKE, which target the XFG variant; Novavax's protein-based Nuvaxovid was also approved for the season. confirmedas of 2026-08-27

    20. [20]

      The 2026-2027 approvals kept the narrower US eligibility set in 2025, covering everyone 65 and older plus younger people with at least one high-risk condition, from age 5 for Comirnaty, 6 months for Spikevax and 12 for mNEXSPIKE. confirmedas of 2026-08-28

    21. [21]

      The FDA memo argued that antibody levels are a surrogate endpoint that does not by itself establish net clinical benefit in healthy people. confirmedas of 2025-08-25

    22. [22]

      The FDA memo said the framework had been published in the New England Journal of Medicine and noted that most peer European nations no longer advise COVID-19 vaccination for healthy people. confirmedas of 2025-08-25

    23. [23]

      In its March 2026 ruling the district court assessed the new ACIP members' credentials, concluding that many lacked the requisite vaccine expertise, and described their appointment as a rushed, informal process. confirmedas of 2026-06-18

    24. [24]

      The Infectious Diseases Society of America welcomed the mFLUSIVA approval, saying the mRNA platform allows streamlined development and rapid responses to viral mutations. confirmedas of 2026-08-06

    25. [25]

      Other 2025 proposals targeted mandates or labelling rather than the vaccines themselves; Florida's governor called for a state ban on mRNA vaccine mandates, and bills in several states sought to ban COVID-19 or mRNA vaccine mandates or to require mRNA technology to be listed among product ingredients. confirmedas of 2025-04-14

    26. [26]

      Supporters of mRNA vaccine bans argued that long-term safety data were lacking and that the COVID-19 vaccines had been approved hastily; public health experts responded that the vaccines had been extensively studied and that banning mRNA would weaken pandemic preparedness. confirmedas of 2025-04-14

    27. [27]

      Montana's 2025 bill to ban mRNA vaccines for humans, HB 371, did not pass. confirmedas of 2025-05-20

    28. [28]

      In February 2026 the South Dakota House rejected HB 1163, which would have barred employers and others from requiring "genetic-based vaccinations", defined to include mRNA vaccines. confirmedas of 2026-07-31

    29. [29]

      All six COVID-19-related bills considered in South Dakota's 2026 session failed, including one that would have required blood centres to ask donors whether they had received a COVID-19 or mRNA vaccine and to label their blood accordingly. confirmedas of 2026-07-31

    30. [30]

      Maryland's 2026 Vax Act (HB 637), signed by the governor on 14 April 2026, requires the state health secretary to issue recommendations for immunizations based on evidence-based scientific and clinical guidance and changes related insurance coverage requirements. confirmedas of 2026-10-10

    31. [31]

      Washington's HB 2242, titled "Preserving access to preventive services by clarifying state authority and definitions", was requested by the governor and insurance commissioner and signed into law on 9 March 2026. confirmedas of 2026-10-10

    32. [32]

      In its appeal brief the government argues that ACIP appointments are not reviewable final agency action, that the plaintiffs lack standing, and that the district court wrongly evaluated appointees' credentials one by one. confirmedas of 2026-06-18

    33. [33]

      As of mid-September 2026, the reconstituted ACIP had not met since the March ruling, and medical societies and state health departments were issuing their own vaccination recommendations. reportedas of 2026-09-15

    Revision history (2)
    1. Page created.
    2. Added the 2026-2027 COVID-19 vaccine approvals and a section on state legislation, covering both proposed mRNA restrictions and state laws on ACIP's role.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "The US mRNA vaccine policy debate, 2025-2026." ContentLora, updated Oct 10, 2026. https://contentlora.com/analysis/us-mrna-vaccine-policy-debate

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    ☰ Contents